Essex Bio-Technology Limited

HKSE 1061.HK

Essex Bio-Technology Limited Debt to Equity Ratio for the year ending December 31, 2023: 0.15

Essex Bio-Technology Limited Debt to Equity Ratio is 0.15 for the year ending December 31, 2023, a -45.97% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Essex Bio-Technology Limited Debt to Equity Ratio for the year ending December 31, 2022 was 0.28, a -13.20% change year over year.
Essex Bio-Technology Limited Debt to Equity Ratio for the year ending December 31, 2021 was 0.33, a -17.41% change year over year.
Essex Bio-Technology Limited Debt to Equity Ratio for the year ending December 31, 2020 was 0.39, a 27.92% change year over year.
Essex Bio-Technology Limited Debt to Equity Ratio for the year ending December 31, 2019 was 0.31, a 51.32% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

HKSE: 1061.HK

Essex Bio-Technology Limited

CEO	Dr. Mia Je Ngiam B.Sc.
IPO Date	June 27, 2001
Location	China
Headquarters	No. 88 Keji 6th Road
Employees	1,459
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Cleaning Supplies Cosmetics Glass Personal Care Pharmaceuticals Plastics

Description

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

Key trends

Past 5 years